CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF43 (ImmuneEditome ID:7594)

1. Gene summary of enriched editing regions for ZNF43

check button Gene summary
Gene informationGene symbol

ZNF43

Gene ID

7594

GeneSynonymsHTF6|KOX27|ZNF39L1
GeneCytomap

19p12

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 43|zinc finger protein 39-like 1 (KOX 27)|zinc finger protein HTF6|zinc finger protein KOX27
GeneModificationdate20230518
UniprotIDP17038;A0A087WSW2;M0R0T7;A0A024R7P7;M0R3D5;M0QYJ6;M0QXI2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:21805174-21806486:-ENST00000357491.9ENSG00000198521.10ZNF43UTR3AluYc,AluSx1,L1MA2,AluSq2chr19:21805174-21806486:-.alignment
chr19:21805174-21806486:-ENST00000594012.4ENSG00000198521.10ZNF43UTR3AluYc,AluSx1,L1MA2,AluSq2chr19:21805174-21806486:-.alignment
chr19:21820116-21821291:-ENST00000354959.7ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000357491.9ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000593551.1ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000594012.4ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000595461.4ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000596899.1ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000598288.4ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000598381.4ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21820116-21821291:-ENST00000599906.4ENSG00000198521.10ZNF43intronicAluSg4,AluSq2,(TAA)n,AluSx,L1MC4,(AT)n,AluYchr19:21820116-21821291:-.alignment
chr19:21824984-21826051:-ENST00000354959.7ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000357491.9ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000593551.1ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000594012.4ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000595461.4ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000596899.1ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000598288.4ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000598381.4ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21824984-21826051:-ENST00000599906.4ENSG00000198521.10ZNF43intronicAluSq2,AluSx4,LTR70chr19:21824984-21826051:-.alignment
chr19:21833356-21837812:-ENST00000354959.7ENSG00000198521.10ZNF43exonicAluSg4,AluSq2,AluSg,AluJo,(GGAA)n,AluSx1,AluSp,AluY,(ATATCT)n,AluSc8,MER4A,(A)nchr19:21833356-21837812:-.alignment
chr19:21841740-21842375:-ENST00000357491.9ENSG00000198521.10ZNF43intronicAluSc,BSR/Betachr19:21841740-21842375:-.alignment
chr19:21841740-21842375:-ENST00000594012.4ENSG00000198521.10ZNF43intronicAluSc,BSR/Betachr19:21841740-21842375:-.alignment
chr19:21841740-21842375:-ENST00000595461.4ENSG00000198521.10ZNF43intronicAluSc,BSR/Betachr19:21841740-21842375:-.alignment
chr19:21841740-21842375:-ENST00000596899.1ENSG00000198521.10ZNF43intronicAluSc,BSR/Betachr19:21841740-21842375:-.alignment
chr19:21841740-21842375:-ENST00000598381.4ENSG00000198521.10ZNF43intronicAluSc,BSR/Betachr19:21841740-21842375:-.alignment
chr19:21847938-21848295:-ENST00000594312.1ENSG00000198521.10ZNF43ncRNA_intronicAluSx,AluSzchr19:21847938-21848295:-.alignment
chr19:21847938-21848295:-ENST00000599414.4ENSG00000198521.10ZNF43ncRNA_intronicAluSx,AluSzchr19:21847938-21848295:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF43


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:21805174-21806486:-BRCAEER5.2804e-10image
ENSG00000198521.10,ZNF43BRCAEAG4.8280e-09image
chr19:21805174-21806486:-KIRPEER1.3435e-02image
ENSG00000198521.10,ZNF43KIRPEAG1.8912e-02image
chr19:21805174-21806486:-LUSCEER2.9159e-04image
ENSG00000198521.10,ZNF43LUSCEAG1.4182e-04image
ENSG00000198521.10,ZNF43STADEAG4.2808e-02image
chr19:21805174-21806486:-THCAEER6.1203e-06image
ENSG00000198521.10,ZNF43THCAEAG6.2908e-06image
chr19:21805174-21806486:-UCECEER1.4676e-04image
ENSG00000198521.10,ZNF43UCECEAG7.8341e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:21805174-21806486:-BLCAPathEER1.7578e-046.6149e-040.1865image
ENSG00000198521.10,ZNF43BLCAPathEAG3.2045e-046.1575e-030.1505image
chr19:21805174-21806486:-BRCAPathEER1.6651e-023.5048e-020.0653image
ENSG00000198521.10,ZNF43ESCACliEAG2.0036e-023.4985e-03-0.5330image
chr19:21805174-21806486:-KIRCPathEER1.4659e-031.4143e-040.1661image
ENSG00000198521.10,ZNF43KIRCPathEAG2.6086e-032.5754e-040.1593image
chr19:21805174-21806486:-LUADPathEER7.4669e-043.4941e-020.1114image
chr19:21820116-21821291:-STADPathEER3.0925e-021.7594e-020.3345image
chr19:21805174-21806486:-THCAPathEER1.5053e-031.0287e-030.1464image
ENSG00000198521.10,ZNF43THCAPathEAG7.5660e-048.1140e-040.1493image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:21805174-21806486:-BLCAEER3.1969e-023.3443e-029.0475e+00image
ENSG00000198521.10,ZNF43BLCAEAG3.1969e-024.6840e-028.0488e+00image
chr19:21805174-21806486:-KIRCEER1.5040e-021.0097e-021.8724e+01image
ENSG00000198521.10,ZNF43KIRCEAG1.0094e-029.8772e-031.8863e+01image
chr19:21833356-21837812:-OVEER1.1256e-031.2820e-049.1137e+01image

Top

3. Enriched editing regions and immune related genes for ZNF43


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:21805174-21806486:-BLCAEERENSG00000271895,RP4-635E18.8-0.46961.3658e-151.9143e-14-0.4054imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_APOPTOSIS
chr19:21805174-21806486:-BLCAEERENSG00000269044,CTC-429P9.3-0.44736.6515e-146.5058e-15-0.4120imageNNNAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
chr19:21805174-21806486:-BLCAEERENSG00000168461,RAB310.39815.2829e-112.1916e-140.4045imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:21805174-21806486:-BLCAEERENSG00000122861,PLAU0.39597.3364e-111.8934e-140.4054imageNNPLAUT_cells_regulatory_(Tregs)GSVA_HALLMARK_APICAL_JUNCTION
chr19:21805174-21806486:-BLCAEERENSG00000029153,ARNTL20.39967.6402e-111.5560e-150.4206imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:21805174-21806486:-THCAEERENSG00000185499,MUC10.26604.0996e-086.4525e-310.4850imageNNMUC1T_cells_regulatory_(Tregs)GSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:21805174-21806486:-THCAEERENSG00000197956,S100A60.24166.7530e-075.4337e-220.4124imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_COAGULATION
chr19:21805174-21806486:-THCAEERENSG00000211890,IGHA20.21412.3322e-052.7483e-220.4151imageNNIGHA2Plasma_cellsGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:21805174-21806486:-THCAEERENSG00000034510,TMSB100.16271.4830e-034.0315e-230.4226imageNNNAPlasma_cellsGSVA_HALLMARK_COAGULATION
chr19:21805174-21806486:-THCAEERENSG00000179862,CITED40.14476.0946e-037.5759e-260.4459imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
chr19:21805174-21806486:-BLCAEERENSG00000271895,RP4-635E18.8-0.46961.3658e-151.9143e-14-0.4054imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_APOPTOSIS
chr19:21805174-21806486:-BLCAEERENSG00000269044,CTC-429P9.3-0.44736.6515e-146.5058e-15-0.4120imageNNNAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
chr19:21805174-21806486:-BLCAEERENSG00000168461,RAB310.39815.2829e-112.1916e-140.4045imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:21805174-21806486:-BLCAEERENSG00000122861,PLAU0.39597.3364e-111.8934e-140.4054imageNNPLAUT_cells_regulatory_(Tregs)GSVA_HALLMARK_APICAL_JUNCTION
chr19:21805174-21806486:-BLCAEERENSG00000029153,ARNTL20.39967.6402e-111.5560e-150.4206imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:21805174-21806486:-THCAEERENSG00000185499,MUC10.26604.0996e-086.4525e-310.4850imageNNMUC1T_cells_regulatory_(Tregs)GSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:21805174-21806486:-THCAEERENSG00000197956,S100A60.24166.7530e-075.4337e-220.4124imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_COAGULATION
chr19:21805174-21806486:-THCAEERENSG00000211890,IGHA20.21412.3322e-052.7483e-220.4151imageNNIGHA2Plasma_cellsGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:21805174-21806486:-THCAEERENSG00000034510,TMSB100.16271.4830e-034.0315e-230.4226imageNNNAPlasma_cellsGSVA_HALLMARK_COAGULATION
chr19:21805174-21806486:-THCAEERENSG00000179862,CITED40.14476.0946e-037.5759e-260.4459imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for ZNF43


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000198521.10,ZNF43
BLCAEAGIRENSG00000159899.10chr935808508:35808683:35808754:35808853-0.30893.8914e-082.0052e-12-0.4145imageNADAR;BCCIP;BUD13;CELF2;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2NADendritic_cells_activatedGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000198521.10,ZNF43
BLCAEAGIRENSG00000139725.3chr12121777757:121781006:121781082:121781192-0.35095.0540e-087.2881e-14-0.4062imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT
chr19:21805174-21806486:-
BLCAEERIRENSG00000130299.12chr1917339388:17339599:17341043:17341056-0.38328.5497e-102.9929e-13-0.4010imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000198521.10,ZNF43
BLCAEAGIRENSG00000163702.14chr39923880:9924137:9924231:9924290-0.27691.0852e-061.6250e-11-0.4100imageNADAR;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184IL17RCT_cells_regulatory_(Tregs)GSVA_HALLMARK_APOPTOSIS
chr19:21805174-21806486:-
BLCAEERIRENSG00000139725.3chr12121777757:121779662:121780871:121781006-0.36761.6653e-098.3019e-13-0.4039imageNNNAMacrophages_M1GSVA_HALLMARK_COMPLEMENT
chr19:21805174-21806486:-
BLCAEERIRENSG00000162910.14chr1228107667:228108321:228108436:228108474-0.35414.6881e-096.9415e-13-0.4071imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000198521.10,ZNF43
BLCAEAGMEXENSG00000112715.16chr643777539:43777665:43778459:43778536:43782010:43782087:43784540:437845620.43942.9562e-123.0319e-160.4313imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZFP36;ZNF184VEGFAT_cells_CD4_naiveGSVA_HALLMARK_APOPTOSIS
chr19:21805174-21806486:-
BLCAEERIRENSG00000139725.3chr12121777757:121781006:121781082:121781192-0.35842.0136e-081.3817e-13-0.4020imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT
chr19:21805174-21806486:-
BLCAEERIRENSG00000139278.5chr1275495576:75498720:75498823:75503853-0.35982.7084e-081.9532e-14-0.4058imageNNNADendritic_cells_activatedGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:21805174-21806486:-
BLCAEERIRENSG00000139278.5chr1275495576:75495662:75498693:75498717-0.35085.1945e-081.2342e-14-0.4087imageNNNAMacrophages_M1GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF43


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:21805174-21806486:-BLCAEERT_cells_CD4_memory_activated1.0062e-060.2658image
chr19:21841740-21842375:-BLCAEERB_cells_memory2.3117e-020.4716image
ENSG00000198521.10,ZNF43BLCAEAGT_cells_CD4_memory_activated3.1181e-060.2538image
chr19:21805174-21806486:-BRCAEERMacrophages_M12.4558e-060.1452image
ENSG00000198521.10,ZNF43BRCAEAGMacrophages_M11.5639e-050.1332image
chr19:21805174-21806486:-CHOLEERMacrophages_M12.3669e-030.6021image
ENSG00000198521.10,ZNF43CHOLEAGMacrophages_M11.5430e-030.6216image
chr19:21805174-21806486:-COADEERT_cells_CD4_naive3.8725e-02-0.2159image
ENSG00000198521.10,ZNF43COADEAGNeutrophils1.2237e-030.3286image
chr19:21805174-21806486:-DLBCEERDendritic_cells_activated1.1019e-030.5750image
ENSG00000198521.10,ZNF43DLBCEAGDendritic_cells_activated1.1453e-030.5735image
chr19:21805174-21806486:-ESCAEERMacrophages_M21.6904e-020.2715image
ENSG00000198521.10,ZNF43ESCAEAGMacrophages_M22.0026e-020.2629image
chr19:21805174-21806486:-GBMEERMacrophages_M01.2217e-04-0.2955image
ENSG00000198521.10,ZNF43GBMEAGMacrophages_M01.4548e-04-0.2924image
chr19:21805174-21806486:-HNSCEERNK_cells_resting2.1554e-040.5300image
ENSG00000198521.10,ZNF43HNSCEAGNK_cells_resting2.1554e-040.5300image
chr19:21805174-21806486:-KIRCEERT_cells_CD4_memory_activated3.2383e-070.2591image
ENSG00000198521.10,ZNF43KIRCEAGT_cells_CD4_memory_activated6.9858e-070.2516image
chr19:21805174-21806486:-KIRPEERNK_cells_resting1.0652e-020.1561image
ENSG00000198521.10,ZNF43KIRPEAGT_cells_CD4_memory_activated7.6507e-060.2700image
chr19:21833356-21837812:-LAMLEERB_cells_memory2.4564e-020.2976image
chr19:21841740-21842375:-LAMLEERDendritic_cells_activated7.6647e-030.2375image
ENSG00000198521.10,ZNF43LAMLEAGNK_cells_activated1.4707e-02-0.2111image
chr19:21805174-21806486:-LGGEERMast_cells_activated4.6154e-020.0872image
ENSG00000198521.10,ZNF43LGGEAGMast_cells_activated4.7894e-020.0866image
chr19:21805174-21806486:-LUADEERMast_cells_resting1.8619e-02-0.1243image
ENSG00000198521.10,ZNF43LUADEAGT_cells_CD4_memory_activated1.7033e-020.1253image
chr19:21805174-21806486:-MESOEERMast_cells_resting1.3639e-03-0.3703image
ENSG00000198521.10,ZNF43MESOEAGMast_cells_resting2.0817e-03-0.3570image
chr19:21805174-21806486:-OVEERT_cells_CD81.9318e-050.2485image
chr19:21820116-21821291:-OVEERT_cells_CD4_memory_activated1.2439e-020.2932image
chr19:21824984-21826051:-OVEERDendritic_cells_activated4.6347e-020.2890image
chr19:21833356-21837812:-OVEERMacrophages_M15.0038e-030.2516image
chr19:21841740-21842375:-OVEERDendritic_cells_resting2.0972e-020.2088image
ENSG00000198521.10,ZNF43OVEAGT_cells_gamma_delta2.1695e-02-0.1350image
chr19:21805174-21806486:-PAADEERNK_cells_activated4.0852e-030.2890image
ENSG00000198521.10,ZNF43PAADEAGNK_cells_activated4.0852e-030.2890image
chr19:21805174-21806486:-PCPGEERT_cells_CD4_memory_resting2.1765e-02-0.1836image
ENSG00000198521.10,ZNF43PCPGEAGT_cells_CD4_memory_resting2.1765e-02-0.1836image
chr19:21805174-21806486:-PRADEERT_cells_follicular_helper1.7227e-03-0.1404image
ENSG00000198521.10,ZNF43PRADEAGT_cells_follicular_helper1.3974e-03-0.1431image
chr19:21805174-21806486:-READEERMacrophages_M27.3710e-030.4174image
ENSG00000198521.10,ZNF43READEAGT_cells_CD4_naive2.1291e-02-0.3587image
chr19:21805174-21806486:-SARCEERMonocytes4.9406e-03-0.1872image
ENSG00000198521.10,ZNF43SARCEAGMonocytes3.8540e-03-0.1919image
chr19:21805174-21806486:-SKCMEERT_cells_CD4_naive4.5191e-030.1870image
ENSG00000198521.10,ZNF43SKCMEAGT_cells_CD4_naive5.5283e-030.1828image
chr19:21805174-21806486:-STADEERB_cells_naive1.5613e-04-0.2489image
chr19:21833356-21837812:-STADEERDendritic_cells_resting2.1611e-030.4122image
chr19:21841740-21842375:-STADEERMonocytes2.0173e-02-0.4026image
ENSG00000198521.10,ZNF43STADEAGB_cells_naive4.6703e-03-0.1855image
chr19:21805174-21806486:-TGCTEERMacrophages_M23.1839e-05-0.3265image
ENSG00000198521.10,ZNF43TGCTEAGMacrophages_M24.9474e-04-0.2757image
chr19:21805174-21806486:-THCAEERT_cells_regulatory_(Tregs)1.1184e-040.1718image
ENSG00000198521.10,ZNF43THCAEAGT_cells_regulatory_(Tregs)1.3256e-040.1699image
chr19:21805174-21806486:-THYMEERDendritic_cells_activated4.8134e-070.4490image
ENSG00000198521.10,ZNF43THYMEAGDendritic_cells_activated7.5861e-070.4420image
chr19:21805174-21806486:-UCECEERDendritic_cells_resting7.7601e-03-0.2066image
ENSG00000198521.10,ZNF43UCECEAGDendritic_cells_resting3.5634e-03-0.2230image
chr19:21805174-21806486:-UCSEERNK_cells_resting9.3529e-040.4415image
ENSG00000198521.10,ZNF43UCSEAGNK_cells_resting3.7069e-030.3919image


Top

6. Enriched editing regions and immune gene sets for ZNF43


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000198521.10,ZNF43BLCAEAG3.3370e-070.27691.3857e-050.23711.0402e-080.30903.5380e-140.4016image
chr19:21805174-21806486:-BLCAEER1.5066e-060.26161.1154e-040.21145.1191e-080.29479.6039e-150.4096image
ENSG00000198521.10,ZNF43BRCAEAG1.5422e-130.22586.6348e-160.24641.7799e-060.14721.6069e-030.0975image
chr19:21805174-21806486:-BRCAEER2.5593e-130.22384.3010e-140.23087.1942e-070.15271.7740e-060.1472image
ENSG00000198521.10,ZNF43LUADEAG1.6650e-050.22423.7874e-040.18582.3599e-050.22022.2158e-050.2210image
chr19:21805174-21806486:-LUADEER2.0583e-050.22301.8137e-030.16433.8716e-050.21572.1378e-070.2700image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:21805174-21806486:-BLCAGSVA_HALLMARK_COMPLEMENTEER1.1917e-160.4354image
ENSG00000198521.10,ZNF43BLCAGSVA_HALLMARK_COMPLEMENTEAG4.9330e-160.4273image
ENSG00000198521.10,ZNF43BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.5197e-170.2579image
chr19:21805174-21806486:-BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.9457e-190.2740image
chr19:21841740-21842375:-BRCAGSVA_HALLMARK_MYC_TARGETS_V2EER3.6674e-02-0.2297image
chr19:21833356-21837812:-BRCAGSVA_HALLMARK_PEROXISOMEEER1.6126e-020.4857image
ENSG00000198521.10,ZNF43CESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.5023e-030.3038image
chr19:21805174-21806486:-CESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.5023e-030.3038image
ENSG00000198521.10,ZNF43COADGSVA_HALLMARK_DNA_REPAIREAG4.8409e-03-0.2883image
chr19:21805174-21806486:-COADGSVA_HALLMARK_ANGIOGENESISEER1.4533e-020.2541image
ENSG00000198521.10,ZNF43ESCAGSVA_HALLMARK_PEROXISOMEEAG1.5396e-02-0.2735image
chr19:21805174-21806486:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.7997e-060.3376image
ENSG00000198521.10,ZNF43GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2112e-050.3247image
chr19:21805174-21806486:-HNSCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.6432e-020.3598image
ENSG00000198521.10,ZNF43HNSCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.6432e-020.3598image
ENSG00000198521.10,ZNF43KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6636e-02-0.2660image
chr19:21805174-21806486:-KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.6636e-02-0.2660image
ENSG00000198521.10,ZNF43KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.8648e-060.2347image
chr19:21805174-21806486:-KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4183e-060.2451image
chr19:21805174-21806486:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.2779e-030.1860image
ENSG00000198521.10,ZNF43KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.5462e-020.1481image
chr19:21841740-21842375:-LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER2.2345e-020.2042image
ENSG00000198521.10,ZNF43LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.9376e-040.3092image
chr19:21824984-21826051:-LAMLGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.1229e-030.4888image
chr19:21833356-21837812:-LAMLGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.3958e-020.2814image
ENSG00000198521.10,ZNF43LGGGSVA_HALLMARK_E2F_TARGETSEAG3.4477e-06-0.2014image
chr19:21805174-21806486:-LGGGSVA_HALLMARK_E2F_TARGETSEER3.9907e-07-0.2195image
chr19:21805174-21806486:-LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.8653e-050.4064image
ENSG00000198521.10,ZNF43LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6482e-050.4088image
chr19:21805174-21806486:-LUADGSVA_HALLMARK_GLYCOLYSISEER1.5133e-080.2936image
ENSG00000198521.10,ZNF43LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.8141e-060.2478image
chr19:21805174-21806486:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.4999e-050.2868image
ENSG00000198521.10,ZNF43LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.0500e-040.2695image
chr19:21805174-21806486:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER7.0716e-030.3148image
ENSG00000198521.10,ZNF43MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG9.3425e-030.3044image
chr19:21820116-21821291:-OVGSVA_HALLMARK_COMPLEMENTEER1.0379e-020.3003image
chr19:21824984-21826051:-OVGSVA_HALLMARK_UV_RESPONSE_UPEER4.8543e-040.4844image
chr19:21805174-21806486:-OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.3504e-100.3565image
chr19:21833356-21837812:-OVGSVA_HALLMARK_PEROXISOMEEER2.8796e-020.1972image
chr19:21841740-21842375:-OVGSVA_HALLMARK_COAGULATIONEER8.9877e-030.2356image
ENSG00000198521.10,ZNF43OVGSVA_HALLMARK_COMPLEMENTEAG1.2586e-040.2237image
ENSG00000198521.10,ZNF43PCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG3.6737e-030.2313image
chr19:21805174-21806486:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER3.6737e-030.2313image
ENSG00000198521.10,ZNF43PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3360e-040.1707image
chr19:21805174-21806486:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.2560e-050.1805image
chr19:21805174-21806486:-READGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER5.0996e-030.4344image
ENSG00000198521.10,ZNF43READGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.7235e-020.3701image
chr19:21805174-21806486:-SARCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.3947e-070.3369image
ENSG00000198521.10,ZNF43SARCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.1478e-070.3445image
chr19:21805174-21806486:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5748e-020.1594image
ENSG00000198521.10,ZNF43SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6805e-020.1579image
chr19:21805174-21806486:-STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.3844e-040.2284image
chr19:21841740-21842375:-STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.0901e-020.4375image
chr19:21833356-21837812:-STADGSVA_HALLMARK_ANGIOGENESISEER7.0812e-030.3657image
ENSG00000198521.10,ZNF43STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.4736e-050.2652image
chr19:21805174-21806486:-TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER1.4862e-040.2991image
ENSG00000198521.10,ZNF43TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.9000e-050.3230image
chr19:21805174-21806486:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.8082e-060.1971image
ENSG00000198521.10,ZNF43THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.6226e-060.2052image
chr19:21805174-21806486:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.1566e-080.4931image
ENSG00000198521.10,ZNF43THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.4230e-080.4835image
ENSG00000198521.10,ZNF43UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.1519e-020.1939image
chr19:21805174-21806486:-UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.3053e-040.2669image
chr19:21805174-21806486:-UCSGSVA_HALLMARK_E2F_TARGETSEER2.0853e-020.3167image
ENSG00000198521.10,ZNF43UCSGSVA_HALLMARK_E2F_TARGETSEAG3.8347e-020.2854image
ENSG00000198521.10,ZNF43UVMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG3.1339e-02-0.4076image
chr19:21805174-21806486:-UVMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.1339e-02-0.4076image


Top

7. Enriched editing regions and drugs for ZNF43


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000198521.10,ZNF43ACCA.770041EAG1.7130e-020.2904image
chr19:21805174-21806486:-ACCA.770041EER1.7130e-020.2904image
chr19:21805174-21806486:-BLCAEHT.1864EER1.2363e-130.3936image
ENSG00000198521.10,ZNF43BLCACMKEAG1.4306e-13-0.3926image
chr19:21833356-21837812:-BRCAFH535EER4.0099e-02-0.4218image
chr19:21805174-21806486:-BRCACGP.082996EER1.9295e-10-0.1954image
chr19:21841740-21842375:-BRCACMKEER2.5158e-030.3274image
ENSG00000198521.10,ZNF43BRCACGP.082996EAG6.8545e-09-0.1781image
chr19:21805174-21806486:-CESCJNK.Inhibitor.VIIIEER1.3093e-02-0.2872image
ENSG00000198521.10,ZNF43CESCJNK.Inhibitor.VIIIEAG1.3093e-02-0.2872image
ENSG00000198521.10,ZNF43CHOLJNK.9LEAG8.3745e-03-0.5360image
chr19:21805174-21806486:-CHOLJNK.9LEER1.0142e-02-0.5248image
chr19:21805174-21806486:-COADABT.263EER3.9999e-040.3615image
ENSG00000198521.10,ZNF43COADAICAREAG5.8566e-04-0.3481image
chr19:21805174-21806486:-DLBCEpothilone.BEER4.8680e-02-0.3693image
ENSG00000198521.10,ZNF43DLBCEpothilone.BEAG4.6052e-02-0.3733image
ENSG00000198521.10,ZNF43ESCAAG.014699EAG1.4483e-02-0.2759image
chr19:21805174-21806486:-GBMBIBW2992EER1.1905e-04-0.2960image
ENSG00000198521.10,ZNF43GBMBIBW2992EAG1.1206e-04-0.2971image
chr19:21805174-21806486:-HNSCGSK.650394EER7.6581e-040.4886image
ENSG00000198521.10,ZNF43HNSCGSK.650394EAG7.6581e-040.4886image
ENSG00000198521.10,ZNF43KICHBIRB.0796EAG2.0661e-03-0.3839image
chr19:21805174-21806486:-KICHBIRB.0796EER2.0661e-03-0.3839image
ENSG00000198521.10,ZNF43KIRCCI.1040EAG3.5212e-04-0.1826image
chr19:21805174-21806486:-KIRCCI.1040EER1.8247e-04-0.1913image
ENSG00000198521.10,ZNF43KIRPAUY922EAG8.8017e-060.2683image
chr19:21805174-21806486:-KIRPCCT018159EER7.6141e-060.2701image
ENSG00000198521.10,ZNF43LAMLKIN001.135EAG3.1295e-03-0.2544image
chr19:21824984-21826051:-LAMLCI.1040EER6.5722e-04-0.5866image
chr19:21833356-21837812:-LAMLMethotrexateEER3.9417e-03-0.3760image
chr19:21841740-21842375:-LAMLBMS.708163EER2.6444e-03-0.2667image
chr19:21805174-21806486:-LGGIPA.3EER1.4370e-040.1655image
ENSG00000198521.10,ZNF43LGGGSK.650394EAG5.4169e-040.1508image
chr19:21805174-21806486:-LIHCLenalidomideEER3.3322e-030.2866image
ENSG00000198521.10,ZNF43LIHCLenalidomideEAG3.3374e-030.2866image
ENSG00000198521.10,ZNF43LUADCMKEAG1.1347e-05-0.2285image
chr19:21805174-21806486:-LUADCGP.60474EER8.9339e-06-0.2323image
ENSG00000198521.10,ZNF43LUSCGefitinibEAG9.9746e-04-0.2299image
chr19:21805174-21806486:-LUSCGefitinibEER1.4988e-04-0.2637image
ENSG00000198521.10,ZNF43MESOCisplatinEAG1.0135e-02-0.3012image
chr19:21805174-21806486:-MESOCisplatinEER1.1907e-02-0.2949image
chr19:21833356-21837812:-OVGDC.0449EER2.4279e-03-0.2710image
chr19:21805174-21806486:-OVEmbelinEER7.0939e-100.3524image
ENSG00000198521.10,ZNF43OVGNF.2EAG1.5707e-02-0.1420image
chr19:21820116-21821291:-OVBMS.708163EER9.0993e-03-0.3054image
chr19:21841740-21842375:-OVGNF.2EER5.4738e-04-0.3084image
chr19:21824984-21826051:-OVAP.24534EER1.4191e-030.4477image
ENSG00000198521.10,ZNF43PCPGDMOGEAG4.7125e-04-0.2767image
chr19:21805174-21806486:-PCPGDMOGEER4.7125e-04-0.2767image
ENSG00000198521.10,ZNF43PRADBAY.61.3606EAG1.0744e-030.1464image
chr19:21805174-21806486:-PRADBAY.61.3606EER4.6852e-030.1268image
ENSG00000198521.10,ZNF43READMG.132EAG6.5083e-03-0.4182image
chr19:21805174-21806486:-READAS601245EER5.5313e-03-0.4307image
ENSG00000198521.10,ZNF43SARCEHT.1864EAG6.9695e-080.3500image
chr19:21805174-21806486:-SARCEHT.1864EER2.1360e-070.3382image
ENSG00000198521.10,ZNF43SKCMGNF.2EAG4.4359e-02-0.1330image
chr19:21805174-21806486:-SKCMGNF.2EER2.8431e-02-0.1448image
chr19:21833356-21837812:-STADAZD.0530EER5.4939e-03-0.3870image
chr19:21841740-21842375:-STADAMG.706EER3.0973e-03-0.4993image
ENSG00000198521.10,ZNF43STADAG.014699EAG3.1131e-030.1937image
chr19:21805174-21806486:-STADAG.014699EER2.3651e-030.2013image
chr19:21805174-21806486:-TGCTBexaroteneEER8.5295e-060.3480image
ENSG00000198521.10,ZNF43TGCTBexaroteneEAG2.1882e-050.3328image
chr19:21805174-21806486:-THCAEmbelinEER5.2773e-210.4032image
ENSG00000198521.10,ZNF43THCAEmbelinEAG2.9069e-180.3759image
ENSG00000198521.10,ZNF43THYMABT.263EAG6.5068e-130.6069image
chr19:21805174-21806486:-THYMABT.263EER9.9837e-140.6234image
ENSG00000198521.10,ZNF43UCECElesclomolEAG5.1448e-040.2644image
chr19:21805174-21806486:-UCECGefitinibEER2.2022e-03-0.2367image
ENSG00000198521.10,ZNF43UCSAMG.706EAG2.5216e-02-0.3073image
chr19:21805174-21806486:-UCSCGP.60474EER4.0910e-02-0.2818image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType